RT Journal Article SR Electronic T1 Patients with Type 2 Diabetes and a GCK variant are still at risk for T2D-related secondary complications JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.12.19.23300223 DO 10.1101/2023.12.19.23300223 A1 Schiabor Barrett, Kelly M. A1 Telis, Natalie A1 McEwen, Lisa M. A1 Burrows, Evanette K. A1 Judge, Daniel P. A1 Pawloski, Pamala A. A1 Grzymski, Joseph J. A1 Washington, Nicole L. A1 Bolze, Alexandre A1 Cirulli, Elizabeth T. YR 2023 UL http://medrxiv.org/content/early/2023/12/19/2023.12.19.23300223.abstract AB Natural HbA1c levels in GCK-MODY patients often sit above the diagnostic threshold for type 2 diabetes (T2D). Standard treatments to lower HbA1c levels are ineffective in these individuals, yet in case studies to date, GCK-MODY patients often evade secondary T2D complications. Given these deviations from a more typical T2D disease course, genetic screening of GCK may be clinically useful, but population studies are needed to more precisely quantify T2D-related outcomes in GCK variant carriers. Using a state-of-the-art variant interpretation strategy based on glucose elevations, we genotyped all individuals in two real-world cohorts (n~535,000) for GCK risk variants and examined rates of T2D and T2D-complications from seven disease categories.We identified 439 individuals with GCK variants predicted to increase glucose (~1/1200). Aligning with their glucose elevations, GCK-MODY variant carriers were 12x as likely, and all other GCK risk carriers 4x as likely, to receive a T2D diagnosis, compared to non-GCK carriers. Surprisingly, GCK risk carriers with T2D develop a range of T2D-related complications at rates comparable to non-GCK T2D patients. Although the penetrance for secondary complications is lower than that for glucose elevations, GCK risk carriers remain at elevated risk of T2D and secondary complications.Competing Interest StatementKMSB, NT, LMM, EKB, NLW, AB and ETC are all employees of Helix. A patent has been filed by Helix for the Power Window analysis technique with ETC, KMSB, and NLW as inventors, and its current status is unpublished (application number 17575894). Funding StatementFunding was provided to the Desert Research Institute by the Renown Institute for Health Innovation and the Renown Health Foundation. Funding was provided to DRI by the Nevada Governor's Office of Economic Development. Funding was provided to the myGenetics program by HealthPartners.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Helix cohorts were reviewed by Salus IRB (Reliance on Salus for all sites) and approved (approval number 21143), the WCG IRB (Western Institutional Review Board, WIRB-Copernicus Group) and approved (approval number 20224919), the MUSC Institutional Review Board for Human Research and approved (approval number Pro00129083), and the University of Nevada, Reno Institutional Review Board and approved (approval number 7701703417). The UK Biobank study was approved by the North West Multicenter Research Ethics Committee, United Kingdom. All participants gave their informed, written consent before participation. All data used for research were de-identified. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesUKB data are available for download (https://www.ukbiobank.ac.uk/) to qualified researchers. The HRN data are available to qualified researchers upon reasonable request and with permission of the HRN Steering Committee and Helix. Researchers who would like to obtain the raw genotype data related to this study will be presented with a Data Use Agreement which requires that participants will not be reidentified and no data will be shared between individuals, third parties, or uploaded onto public domains. The HRN encourages collaboration with scientific researchers on an individual basis. Examples of restrictions that will be considered in requests to data access include but are not limited to: 1. Whether the request comes from an academic institution in good standing and will collaborate with our team to protect the privacy of the participants and the security of the data requested 2. Type and amount of data requested 3. Feasibility of the research suggested 4. Amount of resource allocation for Helix and HRN member institutions required to support a collaboration.